HomeILU • ETR
add
Illumina Inc
Previous close
98.41
Day range
98.40 - 101.10
Year range
62.00 - 132.16
Market cap
18.36B USD
Avg Volume
320.00
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Revenue | 1.16B | 4.98% |
Operating expense | 549.00M | 11.13% |
Net income | 334.00M | 78.61% |
Net profit margin | 28.82 | 70.13% |
Earnings per share | 1.35 | 56.98% |
EBITDA | 294.00M | -8.70% |
Effective tax rate | 11.41% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 1.63B | 33.85% |
Total assets | 6.64B | 5.41% |
Total liabilities | 3.92B | -0.23% |
Total equity | 2.72B | — |
Shares outstanding | 152.90M | — |
Price to book | 5.53 | — |
Return on assets | 8.89% | — |
Return on capital | 11.14% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Net income | 334.00M | 78.61% |
Cash from operations | 321.00M | -11.81% |
Cash from investing | 108.00M | 325.00% |
Cash from financing | -63.00M | -34.04% |
Net change in cash | 368.00M | 42.64% |
Free cash flow | 184.25M | -22.67% |
About
Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets, and serves more than 155 countries.
Illumina's customers include genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Wikipedia
Founded
1998
Headquarters
Website
Employees
8,625
